TPST · XBRL financial data

Tempest Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (TPST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
General and administrative	15,598	9,820	12,113	11,659	13,550	13,969
Operating income (loss)	(35,972)	(26,986)	(34,640)	(29,157)	(42,026)	(26,575)
Interest expense	0	1,282	1,618	1,449	1,316	207
Other income (expense)	90	(34)	549	1,115	1,499	520
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(36,406)	(28,302)	(35,709)	(29,491)	(41,843)	(26,262)
Earnings per share, basic USD per share	(41.03)	(7.47)	(3.09)	(1.91)	(1.50)	(6.33)
Earnings per share, diluted USD per share	(41.03)	(7.47)	(3.09)	(1.91)	(1.50)	(6.33)
Weighted average shares, basic thousands of shares	468	3,790	11,549	15,416	27,902	4,150
Weighted average shares, diluted thousands of shares	468	3,790	11,549	15,416	27,902	4,150

† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TPST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	38,174	51,829	31,230	39,230	30,268	7,707
Prepaid and other current assets	1,929	2,134	1,270	1,133	1,206	562
Total current assets	40,901	68,963	32,950	40,363	31,474	8,269
Property and equipment, net	1,110	1,113	1,060	840	886	605
Right-of-use asset	2,157	3,051	11,650	9,952	8,643	7,540
Total assets	43,409	73,238	46,089	51,603	41,488	16,931
Accounts payable	1,486	991	1,108	845	2,450	1,038
Accrued liabilities	5,525	1,589	2,961	1,673	2,726	937
Current portion of long-term debt	239	—	—	4,285	6,354	0
Total current liabilities	7,987	20,026	7,277	9,411	14,220	3,314
Long-term debt	61	15,069	10,371	6,264	0	—
Lease liability, non-current	1,635	2,026	10,330	9,160	8,142	6,949
Total liabilities	9,683	37,121	27,978	24,835	22,362	10,263
Accumulated deficit	(245,060)	(100,063)	(135,772)	(165,263)	(207,106)	(233,368)
Total stockholders' equity	33,058	36,117	18,111	26,768	19,126	6,668
Total liabilities and equity	43,409	73,238	46,089	51,603	41,488	16,931
Common shares outstanding (cover page) thousands of shares	19,043	7,173	10,562	22,192	45,483	14,344

† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (TPST's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(36,406)	(28,302)	(35,709)	(29,491)	(41,843)	(26,262)
Net cash from operating activities	(30,435)	(25,957)	(31,072)	(27,357)	(33,027)	(26,820)
Purchases of property and equipment	26	135	562	170	435	0
Net cash from investing activities	(26)	(97)	(562)	(170)	(435)	0
Proceeds from issuing common stock	5,453	33,425	8,861	35,602	28,591	6,045
Proceeds from long-term debt	0	15,000	—	—	—	—
Net cash from financing activities	5,386	59,063	11,403	35,602	24,500	4,259
Net change in cash	(24,854)	—	—	—	—	—

† Share count changed about 2x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Yarrow Bioscience	22,925	97	(1,992)*	2.7M	11.5 quarters	Q2 FY26 10-QJun 30, 2026
Rein Therapeutics	8,542	0	(8,640)*	86.3M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.